Welcome !
- Experts in Translational Medicine and Integrative Cancer Care -

Cancer Stem Cell Therapy

Mesenchymal Stem Cell Therapy - MSC

Mesenchymal Stem Cells (MSCs) are adult stem cells that were originally identified in bone marrow as multi-potent cells. Stem cells are characterized by their self-renewal ability and multi-potency. Adipose-derived MSCs have prominent implications in tissue regeneration due to their high cell yield in adipose tissue, the ability to differentiate into multiple lineages and secrete various cytokines, and immunomodulatory effects.

The predominant mechanism by which MSCs facilitate tissue repair is through a paracrine activity and exchange of exosomes. Via the production of a multitude of trophic factors with various properties, MSCs can reduce tissue injury, protect tissue from further degradation, and/or enhance tissue repair.

The secretome of adipose derived MSC consists of various proteins, micro & messenger RNA and extracellular vesicles, such as, but not limited to, exosomes and microvesicles.

It has been shown that the transplantation of mesenchymal stem cells (MSCs) could be an effective therapy for many diseases including blood disease, acute respiratory distress syndrome, spinal cord injury, liver injury, and critical limb ischemia. To date, hundreds of clinical trials using MSCs have been registered in the database of the US national institutes of health. Furthermore, a number of nonregistered clinical studies using MSCs are being performed in many countries. Throughout these studies safety profile has been very good. No side effects have been recorded during autologous use of stem cells and no major side effects during the use of allogeneic stem cells. The use of cell-free treatments is expected to have an even higher safety profile and lower risk of side effects.

The secretome can be harvested and influenced with various techniques and, although research is still needed for a more precise tailoring of the active substances within the secretome for specific diseases, our patented system (patent deposited worldwide) has proven advantages: high yield of active RNA (messenger and micro RNA) contained in exosomes, microvesicles and cytokines, high amount of therapeutic useful micro RNA such as miR-22, miR-146a, miR-219, low amount of cells necessary for autologous uses, easily scalable production for allogeneic use, standardized production enabling degree of uniformity necessary for identification of active ingredients, thus fulfilling the quality considerations of EMA regarding control and validation of manufacturing steps, purity/consistency and phenotypic/genotypic stability.

Our Swiss Partner Med Cell Europe’s system for producing high amount and high quality of active ingredients of the secretomes via EXORAP and EXOPAN will also enable us and our collaborators to develop specific therapies for specific diseases. Med Cell’s research team has developed a therapy for adjuvant cancer therapies, anti-inflammatory and chondroprotective therapies and is currently working on a specific and focused therapy for cardiovascular diseases, diabetes, Multiple Sclerosis, Alzheimer’s disease and wound healing disorders.

Stem Cell Therapy in field of Cancer

The Matryx Cancer Concept follows the “stochastic model of cancer growth because it gives perfect explanation of tumour growth. This theory argues that all cancer cells have the same potential to grow and divide, but each cell chooses at random between self-renewal and differentiation. The cells in a tumor are not in an organized system – any cell has the same intrinsic potential to contribute to tumour growth. The first evidence in favor of cancer stem cells came from studies of human leukemia. Researchers found that only a subset of leukemic cells can cause leukemia when transplanted into a healthy body, the key characteristic of cancer stem cells. Since that discovery, many researchers have found cells with cancer stem cell characteristics in a great variety of human and mouse cancers, including breast, brain, skin, prostate and colonic cancers. In some types of tumor the cancer stem cells are rare, for example in colon cancer. In other types of cancer, such as melanoma, a very large number of the tumour cells have cancer stem cell characteristics.

Copyright © BioMaxx Holding 2015, All right reserved.